COVID-19 studies for: C19 studies:  HC QHC Q IvermectinIVM Vitamin DVitamin D ZincZn REGN-COV2REGN LY-CoVLY RemdesivirRMD
HC Q study #173
Source   PDF   Share   Tweet
See all 181 studies
Early treatment study
Simova et al., New Microbes and New Infections, doi:10.1016/j.nmni.2020.100813 (Peer Reviewed)
Hydroxych loroquine for prophylaxis and treatment of COVID-19 in health care workers
100% reduction in hospitalization and cases with early treatment using HC Q+AZ+zinc. Brief report on healthcare workers in Bulgaria.
0 hospitalizations with treatment vs. 2 for control
0 PCR+ at day 14 with treatment vs. 3 for control
33 treatment patients and 5 control patients.
No serious adverse events. This paper reports on both PEP and early treatment, we have separated the two studies.
hospitalization, ↓96.7%, p=0.01
no virological cure, ↓97.7%, p=0.001, risk of viral+ at day 14
(adjusted for zero)
Source   PDF   Share   Tweet
See all 181 studies
Please send us corrections, updates, or comments.